 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
342 Trials |  |
12240 News |  |
| «12...1415161718192021222324...229230» |
- | Epidaza (chidamide) / Chipscreen, parsaclisib (INCB50465) / Incyte
Enrollment open: PI3K? Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov) - Dec 12, 2023
P1/2, N=28, Recruiting, Sponsor: Henan Cancer Hospital
Not yet recruiting --> Recruiting
- Copiktra (duvelisib) / Secura Bio, Yakult Honsha
Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_788;
P1
In 17 evaluated pts, CAR T-cell expansion by flow cytometry was robust at all dose levels, consistent with prior reports (Figure 1B). Preliminary data from this phase I study suggests that duvelisib as CRS prophylaxis after SoC CAR T-cell therapy is safe and tolerable and may prevent grade 3-4 CRS and delay the onset of CRS.
- | Preclinical, Journal: Fabrication, in-silico, in-vitro, and in-vivo characterization of transferrin-targeted micelles containing cisplatin and gadolinium for improved theranostic applications in lung cancer therapy. (Pubmed Central) - Dec 11, 2023
The biochemical studies have proved the biocompatibility of developed micelles formulations by showing no sign of toxicity in the lungs. The developed micelles have great potential to be utilized in treating and diagnosing a wide variety of cancers.
- | Biomarker, Journal, Tumor microenvironment, Tumor cell: Neuromedin U regulates the anti-tumor activity of CD8 T cells and glycolysis of tumor cells in the tumor microenvironment of pancreatic ductal adenocarcinoma in an NMUR1-dependent manner. (Pubmed Central) - Dec 10, 2023
The developed micelles have great potential to be utilized in treating and diagnosing a wide variety of cancers. In
- | Journal: Red ginseng polysaccharide promotes ferroptosis in gastric cancer cells by inhibiting PI3K/Akt pathway through down-regulation of AQP3. (Pubmed Central) - Dec 9, 2023
Confirmatory in vivo experiments showed that RGP could reduce the growth of implanted tumor, with increased RGP concentration resulting in greater tumor inhibitory effects. RGP might have therapeutic potential against GC, effectively inhibiting the proliferation and viability of AGS cells.
- | sirolimus / Generic mfg.
Journal: FilGAP regulates tumor growth in Glioma through the regulation of mTORC1 and mTORC2. (Pubmed Central) - Dec 9, 2023
The mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that forms the two different protein complexes, known as mTORC1 and mTORC2...Finally, we showed that depletion of FilGAP in KINGS-1 and U-87MG cells significantly reduced spheroid growth. These results suggest that FilGAP may contribute to tumor growth in glioma by regulating mTORC1/2 activities.
- | Journal: The dual HDAC and PI3K inhibitor, CUDC?907, inhibits tumor growth and stem?like properties by suppressing PTX3 in neuroblastoma. (Pubmed Central) - Dec 8, 2023
IHC revealed that the high expression of HDAC1, 2, 3 and CD44 was associated with a poor prognosis of patients with NB. On the whole, these findings indicate that CUDC?907 may be developed into a possible therapeutic approach for patients with NB.
- | Preclinical, Journal: MiR-182 promotes apoptosis of neural cells in cerebral infarction rats by PI3K/AKT signaling pathway. (Pubmed Central) - Dec 8, 2023
Overexpression of miR-182 significantly reduced the protein expression levels of phosphatidylinositol 3-hydroxy kinase (PI3K) and p-AKT. MiR-182 induces apoptosis of neural cells through inhibiting the PI3K/AKT signaling pathway, which plays an important regulatory role in the apoptosis of neural cells in cerebral infarction rats.
- | LY294002 / Eli Lilly
Journal: Emodin exhibits anti-acne potential by inhibiting cell growth, lipogenesis, and inflammation in human SZ95 sebocytes. (Pubmed Central) - Dec 7, 2023
In addition, emodin could decrease the secretion of pro-inflammatory cytokines IL-6 and IL-8, and suppress the expression of NLRP3, capase-1, IL-1?, and IL-18 in SZ95 sebocytes exposed to Cutibacterium acnes. Overall, our study provides preliminary evidence supporting the anti-growth, anti-lipogenic and anti-inflammatory properties of emodin, indicating the potential therapeutic application of emodin for acne treatment.
- | Journal: Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms. (Pubmed Central) - Dec 7, 2023
Finally, ?-KG incubation significantly decreased proinflammatory cytokine secretion from MPN CD14+ monocytes. Our results reveal a previously unrecognized metabolic disorder in conjunction with aberrant PI3K/AKT/mTOR signaling, contributing to platelet hyperreactivity in MPN patients.
- | Journal: Depleting ANTXR1 suppresses glioma growth via deactivating PI3K/AKT pathway. (Pubmed Central) - Dec 7, 2023
ANTXR1 could play an indispensable role in glioma tumorigenesis via activating PI3K/AKT-mediated cell growth. Our study provides a theoretical basis for targeting ANTXR1 as a molecular target in glioma clinical therapeutics.
- | LY294002 / Eli Lilly
Preclinical, Journal: Tsantan Sumtang, a traditional Tibetan medicine, protects pulmonary vascular endothelial function of hypoxia-induced pulmonary hypertension rats through AKT/eNOS signaling pathway. (Pubmed Central) - Dec 6, 2023
TS restored pulmonary arterial endothelial function in HPH rats. The bioactive fraction 17 was screened, which protected hypoxia-injured PAECs via upregulating AKT/eNOS signaling.
- || Review, Journal: Emerging treatment approaches for triple-negative breast cancer. (Pubmed Central) - Dec 5, 2023
These advancements present a promising frontier for tailored interventions with the potential to significantly improve outcomes for TNBC patients. Interestingly, while TNBC poses a complex challenge, it also serves as a paradigm and an opportunity for translational research and innovative therapies in the field of oncology.
- | Journal: Flow induces common and specific transcriptional changes in renal tubular epithelial cells involving the PI3K pathway. (Pubmed Central) - Dec 5, 2023
This suggests that the PI3K pathway is a critical mediator in flow-dependent cellular processes and gene expression, potentially influencing renal development and tissue remodeling. Finally, we derived a cross-cell-line summary of common as well as segment-specific transcriptomic effects, thus providing insights into the molecular mechanisms underlying flow sensing in the nephron tubule.
- | cisplatin / Generic mfg.
Journal: Catalytic Tunable Black Phosphorus/Ceria Nanozyme: A Versatile Oxidation Cycle Accelerator for Alleviating Cisplatin-Induced Acute Kidney Injury. (Pubmed Central) - Dec 5, 2023
However, in the acidic environment of cancers, the presence of H+ inhibited the conversion of Ce4+ to Ce3+, which in turn disrupted the oxidative cycle, resulting in the loss of ROS scavenging ability and ensuring the antitumor effect of DDP. Conclusively, the nanozymes offer an excellent antioxidant for alleviating cisplatin-induced AKI and extensively using in other ROS-based injuries.
- | Piqray (alpelisib) / Novartis
Trial completion date, Combination therapy, Metastases: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 5, 2023
P1, N=46, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Conclusively, the nanozymes offer an excellent antioxidant for alleviating cisplatin-induced AKI and extensively using in other ROS-based injuries. Trial completion date: Oct 2023 --> May 2024
- | Itari (linperlisib) / Shanghai YingLi Pharma
Enrollment closed: Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia (clinicaltrials.gov) - Dec 5, 2023
P1, N=8, Active, not recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Trial completion date: Oct 2023 --> May 2024 Recruiting --> Active, not recruiting
- | Journal: Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles. (Pubmed Central) - Dec 4, 2023
Recruiting --> Active, not recruiting Furthermore, transcriptomic analyses demonstrated that FeO-PASP-DOX-induced apoptosis could be enhanced by FeO-PGA-DHA-induced ferroptosis and FeO-PGA-DHA
- | Journal: FGF10 attenuates allergic airway inflammation in asthma by inhibiting PI3K/AKT/NF-?B pathway. (Pubmed Central) - Dec 4, 2023
Furthermore, transcriptomic analyses demonstrated that FeO-PASP-DOX-induced apoptosis could be enhanced by FeO-PGA-DHA-induced ferroptosis and FeO-PGA-DHA Asthma airway inflammation could be attenuated by Fgf10 in this study, suggesting that it could be a potential therapeutic target.
- | Journal: Blue light photobiomodulation induced apoptosis by increasing ROS level and regulating SOCS3 and PTEN/PI3K/AKT pathway in osteosarcoma cells. (Pubmed Central) - Dec 4, 2023
Meanwhile, SOCS3 is a major inducible anti-tumor molecule, we also found that blue light LED substantially promoted its expression. Thus, this study proposed that bule light PBM may be a hopeful therapeutic approach in OS clinical treatment in the future.
- | Preclinical, Journal: Explore novel molecular mechanisms of FNDC5 in ischemia-reperfusion (I/R) injury by analyzing transcriptome changes in mouse model of skeletal muscle I/R injury with FNDC5 knockout. (Pubmed Central) - Dec 4, 2023
This study demonstrates that FNDC5 deletion exacerbates skeletal muscle I/R injury, potentially involving the upregulation of Col6a2, Enpep, and Mmp11. Additionally, the findings suggest the involvement of the PI3K-Akt pathway in FNDC5 deletion-mediated skeletal muscle I/R injury, providing novel insights into the molecular mechanisms underlying FNDC5's role in this pathological process.
- | Piqray (alpelisib) / Novartis
Journal: Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms. (Pubmed Central) - Dec 4, 2023
Alpelisib demonstrated a tolerable safety profile at a dose of 750mg/week and clinical and metabolic complete remission in a PIK3CA-mutated LCH patient. These data demonstrate PIK3CA as a targetable non-canonical driver of LCH and underscore the importance of mutational analysis-based personalized treatment in histiocytic neoplasms.
- | Mekinist (trametinib) / Novartis, BeiGene, Aliqopa (copanlisib) / Bayer
Preclinical, Journal, Tumor cell: Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis. (Pubmed Central) - Dec 4, 2023
These data demonstrate PIK3CA as a targetable non-canonical driver of LCH and underscore the importance of mutational analysis-based personalized treatment in histiocytic neoplasms. Abrogation of lactate-mediated cross-talk between cancer cells and TAM results in durable ADT-independent tumor control in PTEN/p53-deficient AVPC, and warrants further investigation in clinical trials.
- | LY294002 / Eli Lilly
Journal: Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. (Pubmed Central) - Dec 4, 2023
Increased intestinal urate excretion resulted in spontaneous SUA downregulation during acute gout attacks. Inflammation-induced PI3K/Akt activation and ABCG2 expression in epithelial cells might contribute to the upregulation of intestinal uric acid excretion.
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Journal: CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase ? (CD26). (Pubmed Central) - Dec 4, 2023
These findings underscore the novel role of CXCR2 in the regulation of not only ponatinib-resistant CML cells, but also CML leukemic stem cells. Consequently, our study proposes that targeting CXCR2 holds promise as a viable therapeutic strategy for addressing patients with CML grappling with ponatinib resistance.
- | fenofibrate / Generic mfg.
Journal: Fenofibrate Ameliorates Retinal Pigment Epithelium Injury Induced by Excessive Fat Through Upregulation of PI3K/AKT Signaling. (Pubmed Central) - Dec 3, 2023
Meanwhile, in vivo dosing of fenofibrate ameliorated the downregulated amplitudes of ERG c-wave in HFD-fed mice and suppressed the HFD-induced oxidative injury and inflammatory response in RPE tissues. Our results suggested that fenofibrate ameliorated RPE cell damage induced by excessive fat in vitro and in vivo, in part, through activation of the PI3K/AKT signaling pathway.
- | sorafenib / Generic mfg.
Journal: Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/?-catenin pathways in hepatocellular carcinoma. (Pubmed Central) - Dec 2, 2023
activity, suggesting a novel therapeutic strategy for HCC. Video Abstract.
- ||||||||| Aliqopa (copanlisib) / Bayer
Trial completion date, Trial termination, Combination therapy: CHRONOS-4: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Dec 1, 2023
P3, N=547, Terminated, Sponsor: Bayer
The addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. Base on the study results, company decided to terminate the study.
- | Preclinical, Journal: Browning of Mammary Fat Suppresses Pubertal Mammary Gland Development of Mice via Elevation of Serum Phosphatidylcholine and Inhibition of PI3K/Akt Pathway. (Pubmed Central) - Nov 29, 2023
Furthermore, DOPC suppressed the activation of the PI3K/Akt pathway, while the DOPC-inhibited HC11 proliferation was reversed by SC79, an Akt activator, suggesting the involvement of the PI3K/Akt pathway in the DOPC-inhibited proliferation of HC11. Together, the browning of mammary fat suppressed the development of the pubertal mammary gland, which was associated with the elevated serum DOPC and the inhibition of the PI3K/Akt pathway.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Enrollment closed, Combination therapy, Metastases: Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 29, 2023
P1/2, N=106, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Together, the browning of mammary fat suppressed the development of the pubertal mammary gland, which was associated with the elevated serum DOPC and the inhibition of the PI3K/Akt pathway. Suspended --> Active, not recruiting
- | progesterone / Generic mfg.
Journal: Attenuated AKT signaling by miR-146a-5p interferes with chicken granulosa cell proliferation, lipid deposition and progesterone biosynthesis. (Pubmed Central) - Nov 29, 2023
In summary, the findings revealed that miR-146a-5p suppressed cell growth, lipid deposition, and progesterone biosynthesis via the DEGS1/AKT pathway. These results may further enrich our understandings of how non-coding RNA regulates productive performance in chickens.
- | doxorubicin hydrochloride / Generic mfg.
Journal: USP10 suppresses ABCG2-induced malignant characteristics of doxorubicin-resistant thyroid cancer by inhibiting PI3K/AKT pathway. (Pubmed Central) - Nov 29, 2023
This study demonstrates that USP10 could reduce DOX-induced resistance of TC cells to DOX therapy and could suppress TC malignant behavior by inhibiting the PI3K/AKT pathway. Furthermore, USP10 targeted ABCG2 to inhibit all these malignant processes, therefore, either increasing USP10 expression or inhibiting ABCG2 could be used as novel targets for treating DOX-resistant thyroid cancer.
- | MEN1611 / Menarini, Herceptin (trastuzumab) / Roche
Journal, Combination therapy, Metastases: Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients. (Pubmed Central) - Nov 29, 2023
A slightly lower exposure (i.e., 25% lower) was found for the 3-weekly s.c. schedule. This important outcome confirmed the adequacy of the therapeutic dose administered in the ongoing phase 1b B-PRECISE-01 study in patients with HER2+ PI3KCA mutated advanced/metastatic BC.
- | Journal: D-allose Inhibits TLR4/PI3K/AKT Signaling to Attenuate Neuroinflammation and Neuronal Apoptosis by Inhibiting Gal-3 Following Ischemic Stroke. (Pubmed Central) - Nov 29, 2023
This important outcome confirmed the adequacy of the therapeutic dose administered in the ongoing phase 1b B-PRECISE-01 study in patients with HER2+ PI3KCA mutated advanced/metastatic BC. In summary, D-allose plays a crucial role in inhibiting inflammation after IS by suppressing Gal-3/TLR4/PI3K/AKT signaling pathway in vitro and in vivo.
- | Journal, Real-world evidence, Real-world: Outcomes of COVID-19 in patients with lymphomas participating in registered clinical trials: A real-world study from China in the Omicron outbreak era. (Pubmed Central) - Nov 28, 2023
This study reported similar clinical features of COVID-19 in our cohort with that of non-hematological malignancy (HM) patients, while the proportion of severe/critical COVID-19 and the mortality rate were relatively higher than non-HM patients. Our findings provided valuable experience to aid clinical researchers with managing lymphoma patients participating in registered clinical trials during the ongoing pandemic of the Omicron variant.
- | Journal: Klotho inhibits IGF1R/PI3K/AKT signalling pathway and protects the heart from oxidative stress during ischemia/reperfusion injury. (Pubmed Central) - Nov 27, 2023
Klotho reduced NADPH oxidase 2 (NOX2) (p?=?0.0390), ROS/RNS (p?=?0.0435) and HO (p?=?0.0392) levels, and heart damage (p?=?0.0286) in the hearts subjected to IRI. In conclusion, Klotho contributed to the protection of the heart against IRI and oxidative stress via inhibition of the IGF1R/PI3K/AKT pathway, thus can be recognized as a novel cardiopreventive/cardioprotective agent.
- | Journal: Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells. (Pubmed Central) - Nov 27, 2023
In conclusion, Klotho contributed to the protection of the heart against IRI and oxidative stress via inhibition of the IGF1R/PI3K/AKT pathway, thus can be recognized as a novel cardiopreventive/cardioprotective agent. In the pharmacokinetic study, the administration of 1
- | Journal: The myocardium utilizes a platelet-derived growth factor receptor alpha (Pdgfra) - phosphoinositide 3-kinase (PI3K) signaling cascade to steer towards the midline during zebrafish heart tube formation. (Pubmed Central) - Nov 27, 2023
Moreover, we find that PI3K activity is dependent on and interacts with Pdgfra to regulate myocardial movement. Together our findings reveal an intrinsic myocardial steering mechanism that responds to extrinsic cues during the initiation of cardiac development.
- | sirolimus / Generic mfg.
Journal: Curcumin inhibits the activity and induces apoptosis of activated hepatic stellate cell by suppressing autophagy. (Pubmed Central) - Nov 27, 2023
Our results showed that rapamycin, an autophagy activator, could partly offset the effects of curcumin on autophagy and apoptosis of LX-2 cells, while 3-Methyladenine (3-MA), an autophagy inhibitor, could enhance these effects...Overall, we demonstrated that curcumin could inhibit the activity and promote LX-2 cells apoptosis by suppressing autophagy by activating the PI3K/Akt/mTOR signal pathway. In addition, lipid recovery and energy deprivation due to autophagy inhibition may be the exact mechanism by which curcumin attenuates the pro-fibrotic activity of LX-2.
- | Journal, PD(L)-1 Biomarker, IO biomarker: BATF2 inhibits PD-L1 expression and regulates CD8T cells infiltration in non-small cell lung cancer. (Pubmed Central) - Nov 27, 2023
Based on bioinformatics analysis, we found the function of BATF2 in promoting anti-tumor immune response in patients with NSCLC, which is mediated by BATF2 enhances CD8 T cells infiltration as well as activation. BATF2 from circulating and tissue can serve as an efficient biomarker to predict diagnosis, prognosis and immunotherapy efficacy.
- | Journal: Protein interaction network analysis of mTOR signaling reveals modular organization. (Pubmed Central) - Nov 27, 2023
Using primary fibroblasts from individuals with overgrowth disorders caused by pathogenic PIK3CA or MTOR variants, we find that hyperactivation of mTOR pathway components is reflected in a hyperactive PIN. Our data define a "modular" organization of the mTOR PIN in which coordinated groups of interactions respond to activation or inhibition of distinct nodes, and demonstrate that kinase inhibitors affect the modular network architecture in a complex manner, inconsistent with simple linear models of signal transduction.
- | Journal, Myeloid-derived suppressor cells: Myeloid-derived suppressor cells and tolerogenic dendritic cells are distinctively induced by PI3K and Wnt signaling pathways. (Pubmed Central) - Nov 27, 2023
The identification of PI3K-AKT and Wnt signal transduction pathways as respective inducers of the immunomodulatory capacity of M-MDSCs and TolDCs provides opportunities to overcome suppressive myeloid cells in cancer patients and optimize therapeutic application of TolDCs in patients with autoimmune diseases. Lastly, the observed similarities between generated- and patient-derived M-MDSCs support the use of in vitro generated M-MDSCs as powerful model to investigate the functionality of human MDSCs.
- | Journal: Traditional Medicine Pien Tze Huang Suppresses Colorectal Tumorigenesis through Restoring Gut Microbiota and Metabolites. (Pubmed Central) - Nov 27, 2023
Lastly, the observed similarities between generated- and patient-derived M-MDSCs support the use of in vitro generated M-MDSCs as powerful model to investigate the functionality of human MDSCs. PZH manipulated gut microbiota and metabolites toward a more favorable profile, improved gut barrier function, and suppressed oncogenic and pro-inflammatory pathways, thereby suppressing colorectal carcinogenesis.
- | LY294002 / Eli Lilly
Journal: Grape Seed Proanthocyanidin Ameliorates LPS-induced Acute Lung Injury By Modulating M2a Macrophage Polarization Via the TREM2/PI3K/Akt Pathway. (Pubmed Central) - Nov 27, 2023
In addition, GSP-enhanced PI3K/Akt activity was prevented by TREM2 siRNA. In conclusion, this study demonstrated that GSP could ameliorate LPS-induced ALI by modulating macrophage polarization from M1 to M2a via the TREM2/PI3K/Akt pathway.
- | 5-fluorouracil / Generic mfg.
Journal: Inhibition of PI3K/Akt/mTOR Signaling Pathway Suppresses 5-Fluorouracil Resistance in Gastric Cancer. (Pubmed Central) - Nov 24, 2023
In conclusion, this study demonstrated that GSP could ameliorate LPS-induced ALI by modulating macrophage polarization from M1 to M2a via the TREM2/PI3K/Akt pathway. Silencing of the PI3K/Akt/mTOR signaling pathway suppressed the 5-FU resistance of GC cells.
- | Journal: Methionine Promotes Milk Protein Synthesis via the PI3K-mTOR Signaling Pathway in Human Mammary Epithelial Cells. (Pubmed Central) - Nov 24, 2023
In addition, PI3K inhibition assays confirmed that methionine upregulated the expression of both mTOR and p-mTOR through activation of PI3K. Taken together, these findings suggest that methionine positively regulates milk protein synthesis in MCF-10A cells through the PI3K-mTOR signaling pathway.
- | Journal: Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents. (Pubmed Central) - Nov 22, 2023
Cancers with wild-type BRCA, homologous recombination proficiency, or de novo or acquired resistance to PARP inhibition represent a growing population of patients who may benefit from combinatorial PARP inhibitor strategies. We review targeted inhibitors of angiogenesis, epigenetic regulators, and PI3K, MAPK, and other cellular signaling pathways as inducers of homologous recombination deficiency, providing support for the use of PARP inhibitors in contexts not previously considered susceptible to PARP inhibition.
- | LY294002 / Eli Lilly
Journal: Nodakenin alleviates ovariectomy-induced osteoporosis by modulating osteoblastogenesis and osteoclastogenesis. (Pubmed Central) - Nov 22, 2023
In contrast, LY294002, an inhibitor of PI3K, reversed these changes and inhibited the osteogenic differentiation-enabling effect of NK...In addition, oral administration of NK to mice significantly elevated bone mass and ameliorated ovariectomized (OVX)-mediated bone microarchitectural disorders. In conclusion, these data suggest that NK attenuates OVX-induced bone loss by enhancing osteogenesis and inhibiting osteoclastogenesis.
- | trichostatin A (VTR-297) / Vanda
Preclinical, Journal: Quantitative Proteomics Characterization of the Effect and Mechanism of Trichostatin A on the Hippocampus of Type II Diabetic Mice. (Pubmed Central) - Nov 22, 2023
In conclusion, our study revealed that CAT and PRKAA2 were the key proteins involved in the improvement of DE after TSA treatment. ISOX, apicidin, and panobinostat were promising similar drugs and that GSK-1059615, alisertib, and avrainvillamide-analog-6 were promising ancillary drugs to TSA in the treatment of DE.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Trial suspension, Combination therapy, Metastases: Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 22, 2023
P1/2, N=106, Suspended, Sponsor: National Cancer Institute (NCI)
ISOX, apicidin, and panobinostat were promising similar drugs and that GSK-1059615, alisertib, and avrainvillamide-analog-6 were promising ancillary drugs to TSA in the treatment of DE. Recruiting --> Suspended